Airway Clearance Techniques in Bronchiectasis: Analysis From the United States Bronchiectasis and Non-TB Mycobacteria Research Registry.
airway clearance technique
bronchiectasis
sputum
Journal
Chest
ISSN: 1931-3543
Titre abrégé: Chest
Pays: United States
ID NLM: 0231335
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
04
10
2019
revised:
02
06
2020
accepted:
04
06
2020
pubmed:
6
7
2020
medline:
28
5
2021
entrez:
6
7
2020
Statut:
ppublish
Résumé
In patients with bronchiectasis, airway clearance techniques (ACTs) are important management strategies. What are the differences in patients with bronchiectasis and a productive cough who used ACTs and those who did not? What was the assessment of bronchiectasis exacerbation frequency and change in pulmonary function at 1-year follow up? Adult patients with bronchiectasis and a productive cough in the United States Bronchiectasis and NTM Research Registry were included in the analyses. ACTs included the use of instrumental devices and manual techniques. Stratified analyses of demographic and clinical characteristics were performed by use of ACTs at baseline and follow up. The association between ACT use and clinical outcomes was assessed with the use of unadjusted and adjusted multinomial logistic regression models. Of the overall study population (n = 905), 59% used ACTs at baseline. A greater proportion of patients who used ACTs at baseline and follow up continuously had Pseudomonas aeruginosa (47% vs 36%; P = .021) and experienced an exacerbation (81% vs 59%; P < .0001) or hospitalization for pulmonary illness (32% vs 22%; P = .001) in the prior two years, compared with those patients who did not use ACTs. Fifty-eight percent of patients who used ACTs at baseline did not use ACTs at 1-year follow up. There was no significant change in pulmonary function for those who used ACTs at follow up, compared with baseline. Patients who used ACTs at baseline and follow up had greater odds for experiencing exacerbations at follow up compared with those patients who did not use ACTs. In patients with bronchiectasis and a productive cough, ACTs are used more often if the patients have experienced a prior exacerbation, hospitalization for pulmonary illness, or had P aeruginosa. There is a significant reduction in the use of ACTs at 1-year follow up. The odds of the development of a bronchiectasis exacerbation are higher in those patients who use ACTs continuously, which suggests more frequent use in an ill bronchiectasis population.
Sections du résumé
BACKGROUND
In patients with bronchiectasis, airway clearance techniques (ACTs) are important management strategies.
RESEARCH QUESTION
What are the differences in patients with bronchiectasis and a productive cough who used ACTs and those who did not? What was the assessment of bronchiectasis exacerbation frequency and change in pulmonary function at 1-year follow up?
STUDY DESIGN AND METHODS
Adult patients with bronchiectasis and a productive cough in the United States Bronchiectasis and NTM Research Registry were included in the analyses. ACTs included the use of instrumental devices and manual techniques. Stratified analyses of demographic and clinical characteristics were performed by use of ACTs at baseline and follow up. The association between ACT use and clinical outcomes was assessed with the use of unadjusted and adjusted multinomial logistic regression models.
RESULTS
Of the overall study population (n = 905), 59% used ACTs at baseline. A greater proportion of patients who used ACTs at baseline and follow up continuously had Pseudomonas aeruginosa (47% vs 36%; P = .021) and experienced an exacerbation (81% vs 59%; P < .0001) or hospitalization for pulmonary illness (32% vs 22%; P = .001) in the prior two years, compared with those patients who did not use ACTs. Fifty-eight percent of patients who used ACTs at baseline did not use ACTs at 1-year follow up. There was no significant change in pulmonary function for those who used ACTs at follow up, compared with baseline. Patients who used ACTs at baseline and follow up had greater odds for experiencing exacerbations at follow up compared with those patients who did not use ACTs.
INTERPRETATION
In patients with bronchiectasis and a productive cough, ACTs are used more often if the patients have experienced a prior exacerbation, hospitalization for pulmonary illness, or had P aeruginosa. There is a significant reduction in the use of ACTs at 1-year follow up. The odds of the development of a bronchiectasis exacerbation are higher in those patients who use ACTs continuously, which suggests more frequent use in an ill bronchiectasis population.
Identifiants
pubmed: 32622820
pii: S0012-3692(20)31847-X
doi: 10.1016/j.chest.2020.06.050
pmc: PMC7674976
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1376-1384Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.
Références
Eur Respir J. 2016 Sep;48(3):632-47
pubmed: 27288031
Chest. 2017 May;151(5):982-992
pubmed: 27889361
Am J Respir Crit Care Med. 2007 Feb 15;175(4):367-416
pubmed: 17277290
Lancet Glob Health. 2019 Sep;7(9):e1269-e1279
pubmed: 31402007
Respiration. 1993;60(1):45-50
pubmed: 8469819
Eur Respir J. 2017 Sep 9;50(3):
pubmed: 28889110
BMC Pulm Med. 2014 Jul 01;14:107
pubmed: 24980161
Chronic Obstr Pulm Dis. 2019 Apr 9;6(2):145-153
pubmed: 30974050
Eur Respir J. 2009 Nov;34(5):1086-92
pubmed: 19541717
Cochrane Database Syst Rev. 2013 May 31;(5):CD008351
pubmed: 23728674
Eur Respir J. 2018 Jan 11;51(1):
pubmed: 29326322
Cochrane Database Syst Rev. 2015 Nov 23;(11):CD008351
pubmed: 26591003
Chest. 2018 Nov;154(5):1016-1023
pubmed: 29981718
Eur J Respir Dis Suppl. 1986;147:6-15
pubmed: 3533593
Thorax. 1998 Aug;53(8):685-91
pubmed: 9828857
Am Rev Respir Dis. 1963 Aug;88:199-204
pubmed: 14045224
Thorax. 2015 May;70(5):399-400
pubmed: 25791834
Eur Respir J. 2018 Jan 11;51(1):
pubmed: 29326318
Chest. 2018 Apr;153(4):986-993
pubmed: 29355548
BMC Pulm Med. 2013 Apr 04;13:21
pubmed: 23556995
Semin Respir Crit Care Med. 2015 Apr;36(2):251-66
pubmed: 25826592
Cochrane Database Syst Rev. 2018 Feb 07;2:CD012528
pubmed: 29411860
Chest. 2005 Aug;128(2):739-45
pubmed: 16100162
Chest. 2008 Oct;134(4):815-23
pubmed: 18842914
Eur Respir J. 2017 Jun 8;49(6):
pubmed: 28596426
Am J Respir Crit Care Med. 2018 Jun 1;197(11):1410-1420
pubmed: 29357265
Eur Respir J. 2019 Sep 28;54(3):
pubmed: 31563873
Eur Respir Rev. 2019 Sep 4;28(153):
pubmed: 31484665
Respir Res. 2014 Apr 15;15:44
pubmed: 24731015
Respirology. 2019 Mar;24(3):227-237
pubmed: 30650472
Cochrane Database Syst Rev. 2017 Sep 27;9:CD011699
pubmed: 28952156
Am J Respir Crit Care Med. 2013 Sep 15;188(6):647-56
pubmed: 23898922